To contextualize the predicted immunogenicity of the two patient-specific neoantigens, MED23 (Y573C) and SNTB2 (G322C), we performed a comparative benchmarking analysis against a curated panel of well-characterized antigens relevant to NSCLC. Here, MED23 is linked to non-small cell lung carcinoma.